Impact of HAART on HIV-linked malignancies.
Laurence
Jeffrey
J
D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects / Q000276:immunology; D015994:Incidence; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D008297:Male; D009369:Neoplasms / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology*; D012307:Risk Factors; D012514:Sarcoma, Kaposi / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology